Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy

Daisuke Ennishi, Yasuhito Terui, Masahiro Yokoyama, Yuko Mishima, Shunji Takahashi, Kengo Takeuchi, Hiroaki Okamoto, Mitsune Tanimoto, Kiyohiko Hatake

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Several studies have shown that the frequency of hepatitis C virus (HCV) infection is high in patients with B-cell non-Hodgkin's lymphoma (NHL). In these studies, liver dysfunction during chemotherapy has been demonstrated, but changes in HCV ribonucleic acid (RNA) levels during chemotherapy have not been well documented. In this study, we monitored serum HCV RNA levels and liver function In five HCV-infected patients with B-cell NHL undergoing treatment with rituximab-combination chemotherapy. Increased HCV RNA levels during or after the chemotherapy were observed in all five patients, and a significant increase in transaminases was seen in one case. In this case, serum HCV RNA level dramatically decreased at the time of the increase of transaminases, and this suggested that the cause of liver damage was an immune reaction against hepatocytes with HCV and not any anticancer drug induced liver toxicity. Monitoring of serum HCV RNA levels and transaminases may be helpful to understand the cause of liver dysfunction in patients receiving chemotherapy. However, increases of HCV viral load were not associated with the occurrence of liver dysfunction in this study. Further studies will be necessary to investigate more fully the relationship between changes in HCV viral load and liver function during chemotherapy for HCV-infected patients.

Original languageEnglish
Pages (from-to)59-62
Number of pages4
JournalAmerican Journal of Hematology
Volume83
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

B-Cell Lymphoma
Combination Drug Therapy
Hepacivirus
RNA
Serum
Drug Therapy
Transaminases
Liver Diseases
Liver
Viral Load
Non-Hodgkin's Lymphoma
Rituximab
Virus Diseases
Hepatocytes

ASJC Scopus subject areas

  • Hematology

Cite this

Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. / Ennishi, Daisuke; Terui, Yasuhito; Yokoyama, Masahiro; Mishima, Yuko; Takahashi, Shunji; Takeuchi, Kengo; Okamoto, Hiroaki; Tanimoto, Mitsune; Hatake, Kiyohiko.

In: American Journal of Hematology, Vol. 83, No. 1, 01.2008, p. 59-62.

Research output: Contribution to journalArticle

Ennishi, Daisuke ; Terui, Yasuhito ; Yokoyama, Masahiro ; Mishima, Yuko ; Takahashi, Shunji ; Takeuchi, Kengo ; Okamoto, Hiroaki ; Tanimoto, Mitsune ; Hatake, Kiyohiko. / Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. In: American Journal of Hematology. 2008 ; Vol. 83, No. 1. pp. 59-62.
@article{64972f6803744ad58c571529749ea393,
title = "Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy",
abstract = "Several studies have shown that the frequency of hepatitis C virus (HCV) infection is high in patients with B-cell non-Hodgkin's lymphoma (NHL). In these studies, liver dysfunction during chemotherapy has been demonstrated, but changes in HCV ribonucleic acid (RNA) levels during chemotherapy have not been well documented. In this study, we monitored serum HCV RNA levels and liver function In five HCV-infected patients with B-cell NHL undergoing treatment with rituximab-combination chemotherapy. Increased HCV RNA levels during or after the chemotherapy were observed in all five patients, and a significant increase in transaminases was seen in one case. In this case, serum HCV RNA level dramatically decreased at the time of the increase of transaminases, and this suggested that the cause of liver damage was an immune reaction against hepatocytes with HCV and not any anticancer drug induced liver toxicity. Monitoring of serum HCV RNA levels and transaminases may be helpful to understand the cause of liver dysfunction in patients receiving chemotherapy. However, increases of HCV viral load were not associated with the occurrence of liver dysfunction in this study. Further studies will be necessary to investigate more fully the relationship between changes in HCV viral load and liver function during chemotherapy for HCV-infected patients.",
author = "Daisuke Ennishi and Yasuhito Terui and Masahiro Yokoyama and Yuko Mishima and Shunji Takahashi and Kengo Takeuchi and Hiroaki Okamoto and Mitsune Tanimoto and Kiyohiko Hatake",
year = "2008",
month = "1",
doi = "10.1002/ajh.21022",
language = "English",
volume = "83",
pages = "59--62",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy

AU - Ennishi, Daisuke

AU - Terui, Yasuhito

AU - Yokoyama, Masahiro

AU - Mishima, Yuko

AU - Takahashi, Shunji

AU - Takeuchi, Kengo

AU - Okamoto, Hiroaki

AU - Tanimoto, Mitsune

AU - Hatake, Kiyohiko

PY - 2008/1

Y1 - 2008/1

N2 - Several studies have shown that the frequency of hepatitis C virus (HCV) infection is high in patients with B-cell non-Hodgkin's lymphoma (NHL). In these studies, liver dysfunction during chemotherapy has been demonstrated, but changes in HCV ribonucleic acid (RNA) levels during chemotherapy have not been well documented. In this study, we monitored serum HCV RNA levels and liver function In five HCV-infected patients with B-cell NHL undergoing treatment with rituximab-combination chemotherapy. Increased HCV RNA levels during or after the chemotherapy were observed in all five patients, and a significant increase in transaminases was seen in one case. In this case, serum HCV RNA level dramatically decreased at the time of the increase of transaminases, and this suggested that the cause of liver damage was an immune reaction against hepatocytes with HCV and not any anticancer drug induced liver toxicity. Monitoring of serum HCV RNA levels and transaminases may be helpful to understand the cause of liver dysfunction in patients receiving chemotherapy. However, increases of HCV viral load were not associated with the occurrence of liver dysfunction in this study. Further studies will be necessary to investigate more fully the relationship between changes in HCV viral load and liver function during chemotherapy for HCV-infected patients.

AB - Several studies have shown that the frequency of hepatitis C virus (HCV) infection is high in patients with B-cell non-Hodgkin's lymphoma (NHL). In these studies, liver dysfunction during chemotherapy has been demonstrated, but changes in HCV ribonucleic acid (RNA) levels during chemotherapy have not been well documented. In this study, we monitored serum HCV RNA levels and liver function In five HCV-infected patients with B-cell NHL undergoing treatment with rituximab-combination chemotherapy. Increased HCV RNA levels during or after the chemotherapy were observed in all five patients, and a significant increase in transaminases was seen in one case. In this case, serum HCV RNA level dramatically decreased at the time of the increase of transaminases, and this suggested that the cause of liver damage was an immune reaction against hepatocytes with HCV and not any anticancer drug induced liver toxicity. Monitoring of serum HCV RNA levels and transaminases may be helpful to understand the cause of liver dysfunction in patients receiving chemotherapy. However, increases of HCV viral load were not associated with the occurrence of liver dysfunction in this study. Further studies will be necessary to investigate more fully the relationship between changes in HCV viral load and liver function during chemotherapy for HCV-infected patients.

UR - http://www.scopus.com/inward/record.url?scp=38349006734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349006734&partnerID=8YFLogxK

U2 - 10.1002/ajh.21022

DO - 10.1002/ajh.21022

M3 - Article

C2 - 17712791

AN - SCOPUS:38349006734

VL - 83

SP - 59

EP - 62

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -